http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103755799-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_140efb7e2a330be53d94bda6ad75cbe5
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
filingDate 2014-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_173a6951ce063fceeb725cbe12c0ecb1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_24c2be939b0dee0ccf28ac178cf87d53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97ab3132add80716b1c2773cf093b930
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_833e609256887bb12246525233e54d41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb2947e8d19ea71a43162ac4829422b1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd6e6a71bf2995d94e1254c2b28b97a4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00dc6a0d0676332a358b84fb70505de3
publicationDate 2014-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-103755799-A
titleOfInvention Tumstatin No.30 peptide having anti-tumor effect, and preparation method and application thereof
abstract The invention relates to a tumstatin No.30 peptide having anti-tumor effect, and a preparation method and an application thereof. The amino acid sequence of the tumstatin No.30 peptide is SEQ No.1, and a nucleotide sequence for coding the tumstatin No.30 peptide is SEQ No.2. The tumstatin No.30 peptide is characterized in that nonactive fragments in the No.19 peptide are deleted while the anti-tumor activity of the tumstatin No.41 peptide is maintained, the number of amido acids of the fusion peptide is reduced so that the production cost of the fusion peptide, especially the production of chemical synthesis, is reduced, and furthermore, the safety of drug use is improved.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104593402-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113912739-A
priorityDate 2014-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCO01945
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID562
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID12828
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419578686
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID1285
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419493487
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID317711
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID518605
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID562
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419555934
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID656894
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID518740
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID553354
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419582658
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6305

Total number of triples: 41.